Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $15.53 and last traded at $16.02, with a volume of 42764 shares. The stock had previously closed at $16.23.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on ARVN. Stifel Nicolaus dropped their price objective on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. BTIG Research began coverage on shares of Arvinas in a report on Tuesday, December 10th. They set a "buy" rating and a $69.00 price target on the stock. Wedbush reiterated an "outperform" rating and set a $57.00 price objective on shares of Arvinas in a research report on Tuesday, February 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. Finally, Stephens began coverage on shares of Arvinas in a research report on Monday, November 18th. They set an "overweight" rating and a $55.00 price objective on the stock. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $60.00.
Read Our Latest Stock Analysis on Arvinas
Arvinas Stock Down 1.1 %
The stock's 50 day moving average is $18.36 and its two-hundred day moving average is $22.66. The company has a market capitalization of $1.10 billion, a PE ratio of -5.77 and a beta of 1.88.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm earned ($2.53) earnings per share. On average, sell-side analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.
Insider Buying and Selling
In other Arvinas news, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares of the company's stock, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,572 shares of company stock valued at $695,030 over the last three months. 5.23% of the stock is owned by company insiders.
Hedge Funds Weigh In On Arvinas
Several hedge funds and other institutional investors have recently bought and sold shares of ARVN. JPMorgan Chase & Co. lifted its position in shares of Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after buying an additional 367,343 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in Arvinas in the 3rd quarter valued at $9,989,000. SG Americas Securities LLC lifted its holdings in Arvinas by 228.8% in the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock valued at $622,000 after purchasing an additional 22,564 shares in the last quarter. Wasatch Advisors LP lifted its holdings in Arvinas by 58.3% in the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company's stock valued at $10,737,000 after purchasing an additional 160,510 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Arvinas by 198.9% in the 3rd quarter. Barclays PLC now owns 121,699 shares of the company's stock valued at $2,998,000 after purchasing an additional 80,984 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.
About Arvinas
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
